A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

Study summary

The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine. Researchers also want to learn how internal organs might move during radiation treatment. The goal of the second part of this study is to learn if it is safe to allow slightly more radiation to the normal esophagus when spinal tumors close by are being treated. This may result in better tumor control.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSpinal SBRT (Standard Dose) and Spinal SBRT (Higher Dose)

Plus 2 other study approaches.

Who it may be forSpinal Tumor

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 12, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?M.D. Anderson Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Not applicable
Sponsor: M.D. Anderson Cancer Center
Interventions being studied: Radiation: Spinal SBRT (Standard Dose); Radiation: Spinal SBRT (Higher Dose); Procedure: Gold Seed Implantation; Behavioral: Questionnaires

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. STAGE 1: \>/= 18 years old 2. STAGE 1: Pathologically confirmed diagnosis of cancer, including, but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and carcinoma of unknown primary 3. STAGE 1: Signed informed consent 4. STAGE 2: 1-3 above, and Patients undergoing single fraction spinal SBRT

Reasons someone may not be able to joinExclusion criteria

1. STAGE 1: Patient with radiosensitive histologies (lymphoma, multiple myeloma, small cell carcinomas, germ cell tumors) 2. STAGE 1: Extensive (\> 50%) height loss of the involved vertebral body 3. STAGE 1: Inability to tolerate lying flat on treatment table for greater than 30 minutes 4. STAGE 1: Pregnancy 5. STAGE 2: Prior irradiation of the spine site and level to be treated 6. STAGE 2: Patients with primary disease arising in the posterior elements of the VB in question 7. STAGE 2: History of Barrett's esophagus, esophageal webbing, stricture, or fistula 8. STAGE 2: Prior radiation to the esophagus

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Texas MD Anderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2026. Always confirm current availability with the study team.

View original record ↗